PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.12758185383148452 | N/A |
Market Cap | $40.95M | N/A |
Shares Outstanding | 321.01M | 1.30% |
Employees | 0 | N/A |
Shareholder Equity | 3.89M | -50.42% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -6.61 | N/A |
P/S Ratio | 21.60 | N/A |
P/B Ratio | 10.53 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -1.0725 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $1.90M | N/A |
Earnings | -$4.17M | N/A |
EPS | -0.0193 | N/A |
Earnings Yield | -0.1513 | N/A |
Gross Margin | 0.7211 | N/A |
Operating Margin | -1.31 | N/A |
Net income margin | -2.20 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $4.12M | N/A |
Total Debt | $704.36K | N/A |
Cash on Hand | $1.82M | N/A |
Debt to Equity | 0.3870 | 102.37% |
Cash to Debt | $2.58 | 47.91% |
Current Ratio | $2.24 | -29.93% |